drugset / Trial / NCT00488215

A Trial in Healthy Volunteers, to Evaluate the Tolerability and Cardiac Safety of Prucalopride

NCT00488215

Phase 1 Completed 32 enrolled Movetis
RandomizedCrossoverDouble-blind

Summary

An escalating dose of prucalopride up to a maximum of 20 mg was given once daily to 32 healthy volunteers to determine safety at the maximum tolerable dose or at 20 mg.

Timeline

Start
2000-01
Primary completion
2000-03
Completion
2000-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prucalopride Small molecule 20 mg Oral

Indications